Journal
ONCOLOGIST
Volume 17, Issue 2, Pages 267-273Publisher
WILEY
DOI: 10.1634/theoncologist.2011-0219
Keywords
Early palliative care; Efficacy of palliative care; Symptom control; Cost of care; Quality care; Supportive care
Categories
Funding
- Ameritox
- Archimedes Pharmaceuticals
- Boston Scientific
- Covidien Mallinckrodt Inc.
- Endo Pharmaceuticals
- Forest Labs
- K-Pax Pharmaceuticals
- Meda Pharmaceuticals
- Medtronics
- Otsuka Pharma
- ProStrakan
- Purdue Pharma
- Salix
- St. Jude Medical
- Pfizer
- Lilly
- Bristol-Myers Squibb
- KangLaiTe
- Alexion
- Biovex
- DARA
- MiCo
- NIH
- Robert Wood Johnson Foundation
- AHRQ
- Amgen
- Helsinn Therapeutics
- Novartis
- National Institutes of Health through MD Anderson's Cancer Center [CA016672]
Ask authors/readers for more resources
Cancer patients develop severe physical and psychological symptoms as a result of their disease and treatment. Their families commonly suffer great emotional distress as a result of caregiving. Early palliative care access can improve symptom control and quality of life and reduce the cost of care. Preliminary results show that early palliative care access can also extend survival. Unfortunately, only a minority of cancer centers in the U.S. have the two most important resources for palliative care delivery: outpatient palliative care centers and inpatient palliative care units. In this article, we use a case presentation to discuss the impact of early palliative care access in light of the currently available evidence, and we recommend ways to improve early access to palliative care through education and research. The Oncologist 2012;17:267-273
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
